Clinical Updatesbreast cancerendocrine resistance
First-Line Camizestrant for ESR1-Mutated Advanced Breast Cancer: Redefining Endocrine Therapy Resistance
By MedXY|Oct 1, 2025
Next-generation SERD camizestrant significantly prolongs progression-free survival over aromatase inhibitors or fulvestrant in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, with favorable safety and quality-of-life profil
